The ultimate goal of Dr Janji's research team is to provide the proof of concept that targeting autophagy could improve the efficacy of current immunotherapies, notably those based
on immune checkpoint blockades.
Not exact matches
Allison pioneered
immune checkpoint blockade, an approach that treats the
immune system, rather than the tumor directly, by blocking molecules
on T cells that shut those attack cells down, protecting tumors from
immune response.
Checkpoint blockade: Fewer but stronger results Allison pioneered immune checkpoint blockade, an approach that treats the immune system, rather than the tumor directly, by blocking molecules on T cells that shut those attack cells down, protecting tumors from immune
Checkpoint blockade: Fewer but stronger results Allison pioneered
immune checkpoint blockade, an approach that treats the immune system, rather than the tumor directly, by blocking molecules on T cells that shut those attack cells down, protecting tumors from immune
checkpoint blockade, an approach that treats the
immune system, rather than the tumor directly, by blocking molecules
on T cells that shut those attack cells down, protecting tumors from
immune response.
In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after
checkpoint blockade, to develop algorithms to identify and predict the best antigens
on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of
immune cells for adoptive cell therapy.
Allison is the person responsible for developing the
checkpoint blockade approach to cancer immunotherapy: antibodies are used to target specific molecules
on immune cells, which empowers them to find and attack cancer cells.